Doxorubicin-Ferein, lyophilizate 10 mg

Pharmacotherapeutic group

Antitumor drug, antibiotic

ATX code

L01DB01

Pharmacodynamics: Antitumor antibiotic of the anthracycline series isolated from a culture of Streptomyces peucetius var. caesius.
It has antimitotic and antiproliferative effects. Mechanism of action is in interaction with DNA forming free radicals and direct effect on cell membranes with inhibition of nucleic acids synthesis. Cells are sensitive to the drug in S- and G2-phases.
Pharmacokinetics: Absorption – high distribution – relatively uniform. Across the blood-brain barrier does not penetrate. Binding with plasma proteins is about 75%. It is metabolized in the liver to form active metabolite doxorubicinol. Enzymatic reduction of doxorubicin under the influence of oxidase reductases and dehydrogenases leads to the formation of free radicals, which may contribute to the cardiotoxic effect. After IV administration it rapidly disappears from the blood concentrating in the liver kidneys myocardium spleen lungs. Half-life is 20-48 h for doxorubicin and doxorubicinol. Excretion: with the bile – 40% unchanged for 7 days with the urine – 5-12% of doxorubicin and its metabolites for 5 days.

Indications

Active ingredient

Composition

Each vial contains

The active ingredient:

doxorubicin hydrochloride 10 mg.

The excipients:

Mannitol.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Pregnancy use